Pacific Edge Grows Cxbladder Volumes as Medicare Policy Tailwinds Build

An update from Pacific Edge Limited ( (PFGTF) ) is now available.

Pacific Edge reported a 2.7% rise in total laboratory throughput to 5,582 Cxbladder tests in Q4 2026, driven by growth in both the U.S. and Asia-Pacific despite Medicare non-coverage, winter storm disruptions and a reduced sales force. The company highlighted increased sales force productivity, with more tests per sales FTE and per ordering clinician, as Triage continued to replace Detect in the U.S. portfolio.

Strategic momentum gathered around a potential Medicare policy shift after strong expert support for Cxbladder at a Novitas advisory meeting, reinforcing expectations of a positive local coverage determination in the coming year. Pacific Edge also secured major new reimbursement wins with Blue Cross Blue Shield plans and Highmark in the U.S., gained adoption at leading hospitals in Singapore and Australia, and advanced intellectual property protection for Triage Plus, underscoring its ambition to consolidate first-mover leadership in bladder cancer diagnostics.

More about Pacific Edge Limited

Pacific Edge Limited is a New Zealand-headquartered global cancer diagnostics company specialising in non-invasive genomic urine tests for bladder cancer, marketed under the Cxbladder brand. It develops and commercialises diagnostic and prognostic tests for patients with hematuria or under surveillance for recurrent urothelial cancer, serving markets in the U.S., Australasia, Asia, South America and Israel through CLIA-certified laboratories in New Zealand and the U.S.

See more insights into PFGTF stock on TipRanks’ Stock Analysis page.